kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human Azurocidin /AZU1 Protein, 100µg  

Recombinant Human Azurocidin /AZU1 Protein, 100µg

Recombinant Human Azurocidin  / CAP37 / AZU1 Protein (rhAZU1 / HBP) Ile 27 - Pro 250 was produced in human 293 cells (HEK293), His Tag

Synonym: recombinant, human, protein, AZU1, Azurocidin, HBP, AZAMP, AZU

More details


Availability: within 7 days

312,00 €

Azurocidin (AZU1) is also known as Heparin-binding protein (HBP), Cationic antimicrobial protein CAP37, is a neutrophil granule-derived antibacterial and monocyte- and fibroblast-specific chemotactic glycoprotein. which belongs to the peptidase S1 family and elastase subfamily. AZU1 / HBP contains 1 peptidase S1 domain. AZU1 binds heparin. The cytotoxic action of AZU1 is limited to many species of Gram-negative bacteria; this specificity may be explained by a strong affinity of the very basic N-terminal half for the negatively charged lipopolysaccharides that are unique to the Gram-negative bacterial outer envelope. AZU1 may play a role in mediating recruitment of monocytes in the second wave of inflammation.

Recombinant Human Azurocidin, His Tag (AZ1-H5225) is expressed from human 293 cells (HEK293). It contains AA Ile 27 - Pro 250 (Accession # AAH69495).
Predicted N-terminus: Ile 27

Molecular Characterization
rhAZU1 / HBP, fused with 6×His tag at the C-terminus, has a calculated MW of 25 kDa. The predicted N-terminus is Ile 27. DTT-reduced Protein migrates as 32-40 kDa due to glycosylation.

Less than 1.0 EU per μg of the rhAZU1 / HBP by the LAL method.

>95% as determined by SDS-PAGE.

Refer to data sheet

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4C-8C); After reconstitution under sterile conditions for 1 month (4C-8C) or 3 months (-20C to -70C).


(1) Wasiluk K.R., et al., 1991, Infect. Immun. 59:4193-4200.
(2) Miyasaki K.T., 1992, Infect. Immun. 60:4973-4975.
(3) Linder A., 2009, Clin. Infect. Dis. 49 (7): 1044–50.